Lord’s Mark Industries Gets Nod for Final Clinical Trials of AI Breast Cancer Screening Device
New Delhi [India], September 23: Lord’s Mark Industries Limited has informed the BSE that its Technical Committee has approved the final clinical trial stage for its AI-powered, radiation-free wearable breast...
New Delhi [India], September 23: Lord’s Mark Industries Limited has informed the BSE that its Technical Committee has approved the final clinical trial stage for its AI-powered, radiation-free wearable breast cancer screening device, with trials planned across the USA, Great Britain and Europe. The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The device, developed in collaboration with the Centre for Materials for Electronic Technology (C-MET), uses thermal sensors and AI-based temperature mapping to identify abnormalities without radiation. According to the company, clinical trials in India have been completed, with Phase 2 trials targeting cell-level detection accuracy of 98% set to begin from January 2027 across India, the USA, Europe and Great Britain.
